PD37-01 ASSOCIATION BETWEEN TESTOSTERONE THERAPY AND THROMBOTIC EVENTS IN ELDERLY MEN

Abstract

INTRODUCTION AND OBJECTIVES: The association between testosterone therapy (TT) and thrombotic risk in elderly men remains controversial. We evaluated the prevalence of thrombotic events and all-cause mortality in men older than 65 years with hypogonadism treated with testosterone therapy. We compared men treated with testosterone to an age and comorbidity matched cohort of hypogonadal men not treated with TT. METHODS: After IRB approval, we retrospectively reviewed the charts of 217 hypogonadal men (2 AM T 3 years), availability of serum testosterone levels before and after therapy and of a control group (hypogonadal men not treated with TST) for comparison. In addition, we performed a power analysis (80% power), and confirmed that the sample size studied was adequate. Limitations included retrospective study design, a small sample size and lack of information on cause of death. CONCLUSIONS: Consistent with the majority of the studies in the literature, there was increased all-cause mortality in hypogonadal men not treated with testosterone compared to men who received testosterone therapy. There was no difference in prevalence of MI, TIA/ CVA, or PE between patients who were treated with testosterone and hypogonadal men not treated with testosterone.